Given the survival advantage, high-dose therapy (HDT) remains the standard of care for patients with multiple myeloma eligible for the procedure. For those undergoing HDT, initial therapy aimed at reducing tumor burden is given prior to stem cell harvest. Various regimens, mostly variations of VAD (vincristine, doxorubicin, dexamethasone), are used for induction therapy. We retrospectively evaluated if single agent dexamethasone would be an effective induction therapy, given that it is the most active drug in these combinations. A total of 35 patients who received induction therapy with dexamethasone alone were compared to a similar group of 72 patients who received VAD as the initial therapy. We found a 63% response rate with dexamethasone compared to 74% with VAD (P ¼ 0.25). Including minimal responses, the overall response rate for Dex and VAD was 74 and 86%, respectively (P ¼ 0.13). The overall and complete response rates to transplant, respectively, were 97 and 26% for the dexamethasone group and 100 and 39% for the VAD group; P ¼ 0.33 and 0.18. No significant differences were observed in the progression-free and overall survival at 1 year post transplant. Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma.
estimates, there will be 14 600 new cases of multiple myeloma in the US and 10 900 will die of the disease. 1 Myeloma predominantly affects older individuals with a median age of onset in the mid sixties. The median survival from diagnosis with conventional chemotherapy is 3-4 years. 2, 3 Several combination chemotherapies have been studied in the treatment of this disease, but none have improved the survival compared to melphalan and prednisone, which was introduced in the early seventies. 4 Introduction of high-dose melphalan therapy in the eighties 5 and the subsequent concept of autologous stem cell rescue 6 resulted in significant improvement in response rates to therapy as well as survival. [7] [8] [9] More recently, some studies have suggested a better outcome with tandem autologous transplants. 10, 11 Traditionally, initial therapy for myeloma has been the combination of melphalan and prednisone. However, with increasing use of autologous transplantation, there was recognition of the fact that alkylator therapy can damage stem cells and compromise the yield of hematopoietic progenitor cells for transplantation. 12 This has led to the use of other chemotherapy combinations prior to stem cell collection, the most commonly used regimen currently being various modifications of the VAD (vincristine, doxorubicin, dexamethasone) regimen. 13 It is not clear how much the initial reduction in tumor burden contributes to the overall transplant outcomes. We and others have shown that patients who are refractory to initial chemotherapy do as well as those who obtain a response to the initial therapy. 14, 15 Given this scenario, it is appealing to use agents that are associated with less toxicity than regimens like VAD. In all the different regimens used for treatment of myeloma, steroids either in the form of dexamethasone or prednisone are one of the most active components. In this study, we have reviewed the results of using dexamethasone as a single agent for induction therapy in patients with newly diagnosed myeloma prior to autologous transplant and have compared it to a similar population who underwent induction therapy with VAD.
Patients and methods
A total of 107 patients with multiple myeloma, who underwent stem cell collection and transplantation between April 1995 and April 2002, form the subjects for this study.
Specifically, 35 patients who received dexamethasone as a single agent for induction therapy (Dex group) are compared to 72 patients who received initial therapy with VAD (VAD group). Only patients proceeding to an early transplant after one induction regimen were included for this study. Data pertaining to the transplant patients are captured prospectively in a database that is continuously updated. No patients were lost to follow up. All patients had provided written informed consent for use of their medical records. Approval of the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
In patients receiving single agent dexamethasone, it was given at 40 mg/day on days 1-4, 9-12, and 17-20 for four cycles. The remaining patients initially received infusional chemotherapy with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy for four cycles. The dexamethasone was administered as originally described at 40 mg/day on days 1-4, 9-12, and 17-20 for all treatment cycles. 13 None of the patients had exposure to melphalan prior to stem cell harvest. The use of dexamethasone represented a change in the institutional clinical practice.
After the completion of 3-4 cycles of induction therapy, irrespective of the response, patients proceeded to stem cell collection. By selecting a uniform group of patients who proceeded directly to transplant after 3-4 cycles of induction therapy and including consecutive patients who came to transplant after either of these therapies, we have considerably decreased introduction of bias. In all but one patient, stem cells were collected after initial administration of cyclophosphamide 1.5 g/m 2 per day for 2 consecutive days. This was followed by sargramostim (GM-CSF) or filgrastim (GCSF) at 5 mg/kg starting on day 3 and continuing until collection was complete. Apheresis was performed once the total white blood cell count exceeded 500/ml. The remaining patient had stem cells collected using filgrastim alone administered subcutaneously (5 mg/kg) daily until the completion of peripheral blood stem cell collection with apheresis beginning on the fifth day after starting G-CSF. Prior to 1997, the target for the apheresis procedure was 5 Â 10 8 mononuclear cells/kg, which was subsequently replaced by quantitation of CD34 þ cells and the target became 5 Â 10 6 CD34 þ cells/kg. Following the stem cell harvest, all patients proceeded to immediate transplantation. A total of 73 patients (68%) underwent conditioning with melphalan alone, given at 200 mg/m 2 given as a single dose on day À1. In three additional patients, melphalan dose was reduced to 100-140 mg/m 2 for advanced age, renal insufficiency, or poor performance status. The remaining 31 patients (29%) received melphalan at 140 mg/m 2 on day À4, followed by total body radiation of 2 Gy twice daily on days À3 to À1.
Similar criteria were used for assessment of response to the induction therapy and to high dose therapy (HDT) with minor differences. For evaluating the response to the induction therapy, complete response (CR) was defined as lack of detectable monoclonal (M) protein in serum and urine by immunoelectrophoresis and immunofixation, complete disappearance of soft-tissue plasmacytomas and no increase in lytic bone lesions. Objective response was defined as reduction of serum M protein and 24-h urinary light chain excretion by at least 50% accompanied by a similar reduction of soft-tissue plasmacytomas if present. In those with nonsecretory myeloma, reduction in the bone marrow plasma cell infiltrate by 50% constituted partial response. A decrease in the corresponding values by at least 25% was considered as having a minor response for the induction therapy. For evaluation of the response to transplant, CR was defined as above. A bone marrow biopsy was not consistently performed to evaluate response and does not form part of the definition. Partial response was defined as reduction of serum M protein by at least 50% accompanied by a similar reduction of soft-tissue plasmacytomas if present. Patients with urine light chain only required a reduction of urinary light chain excretion to 10% or less of the pretreatment value. Relapse or progression was defined as a 50% increase in the serum M protein or 24-h urinary M protein excretion over the lowest response level. In those patients who achieved a CR, any detection of M protein by immunofixation, increase in the size of existing lytic bony lesions or soft-tissue plasmacytomas, or appearance of new lytic lesions constituted relapse (or progression), even if not accompanied by measurable changes in the M protein.
Bone marrow plasma cell labeling index (PCLI), cytogenetics, b 2 microglobulin (b 2 M), and other laboratory variables were assessed pre-transplantation. The labeling index, which is a measure of the cell kinetics, was determined using a slide-based immunofluorescence method on bone marrow samples, as previously described 16 and is classified as high when X1%.
The w 2 and Fisher exact tests were used to compare differences among the patient groups for nominal variables and the nonparametric test (Mann-Whitney test) was used for continuous variables. The Kaplan-Meier analysis was used for analyzing time to event variables such as overall and progression-free survival, the time to platelet and neutrophil engraftment, and time to response. Owing to the lesser degree of censoring for progression-free survival, this variable was explored further in a univariate and multivariable setting with other prognostic factors of interest: age at transplant, time from diagnosis to transplant, serum M spike at transplant, PCLI (41 vs o1), the conditioning regimen, and whether or not the patient had a CR with transplant. Cox proportional hazards models were used to evaluate the multivariable model for progression-free survival. In addition, logistic regression models were used to identify factors associated with the incidence of a CR.
To correct for the multiple comparisons made in these analyses, the Bonferroni correction was used. Specifically, with approximately 37 variables evaluated in a univariate manner between the two groups of interest for baseline features and those at the time of transplant (ie Dex vs VAD), statistical significance was declared at Po0.00135 (Tables 1 and 2) . However, for model-building purposes in the multivariable logistic and Cox regression models, variables that had a P-value of o0.05 in the univariate setting were included in the multivariable models. All Pvalues represented were two-sided. Overall survival was not formally evaluated through complex modeling here due to the low number of events and relatively immature followup for this end point. However 1-and 2-year estimates were calculated based on the level of follow-up available for this patient cohort.
Results
The study cohort consisted of 107 patients, of which 62 were male (58%), with a median age at diagnosis of 56.5 years (range 29-72). Baseline demographic characteristics at diagnosis were similar in the two groups except for slightly higher b 2 M in the VAD group (Table 1) . Clinical characteristics including disease stage and proportion of patients with IgA myeloma were similar among the two groups. In all, 74 patients (69%) were alive at the time of the last follow-up with a median post transplant follow-up of 30 months (range; 17-105 months). The median followup was shorter for the Dex group (25.5 months, range; 17-42 months), compared to 42 months (range; 21-105 months) for the VAD group.
The median duration of induction therapy was 3.6 months (range; 1.2-5.6 months) in the Dex group and was comparable to the 3.2 months (range; 1.5-7 months) in the VAD group. A total of 53 patients (74%) in the VAD group had a partial response to the induction therapy compared to 22 patients (63%) in the Dex group (P ¼ 0.25). Overall response rates including minimal responses (25-49% reduction in M protein) were 86% for the VAD group and 74% for the Dex group (P ¼ 0.13). There were no CRs to induction therapy. Details of adverse events with induction therapy were not available for patients receiving therapy outside of the institution and were not analyzed.
The clinical characteristics were similar between the two groups at the time of transplant except for the time from diagnosis to transplant (slightly higher for the VAD group) and the harvested CD34 cell count ( Table 2 ). All patients in the Dex group received melphalan only conditioning compared to 57% in the VAD group, the rest receiving melphalan/TBI (Po0.001). Time to engraftment for neutrophils (4500) and platelets (450 K) was shorter for the VAD group compared to the Dex group (Po0.001 and Po0.001, respectively).
All patients in the VAD group had an objective response to transplant compared to 34 patients (97%) in the Dex group (P ¼ 0.15). The CR rate following HDT was 26% for the Dex group compared to 39% for VAD group (P ¼ 0.18). In addition to induction therapy and the incidence of CR following transplant, we also looked at the conditioning regimen (melphalan 200 vs melphalan þ TBI; P ¼ 0.14) and b 2 -microglobulin (42.7 vs o2.7; P ¼ 0.85). None of these factors was significantly associated Autologous transplantation in myeloma S Kumar et al with the incidence of CR post transplant, even when forced in a multivariable model looking at combinations of these various risk groups. The 1-year overall survival rate from transplant was 94% for the Dex (Dex) group compared to 90% for the VAD group, and the 2-year overall survival rate from transplant was 85% for the Dex group vs 78% for the VAD group (P ¼ 0.32). The median survival for the Dex group had not yet been reached, and was 60 months for the VAD group (Figure 1) .
Overall, 64 patients (60%) had relapsed or progressed. The 1-year progression-free survival from transplant was 76% for the Dex group compared to 77% for the VAD group, and the 2-year rate was 40% for the Dex group vs 54% for the VAD group (P ¼ 0.34). The median progression-free survival for the Dex group was 20 months (95% CI: 15 months -not yet reached) vs 29 months for the VAD group (95% CI: 19-35 months) (Figure 1 ). In addition to evaluating differences in progression-free survival between induction groups, other factors were assessed: age at transplant, time from diagnosis to transplant, serum M spike at transplant, whether or not the patient had a CR with transplant, the conditioning regimen, and PCLI (X1 vs o1). Of these, the only factors with P-values o0.05 in the univariate analyses to be considered in a multivariable model were the incidence of CR post transplant (P ¼ 0.0048) and PCLI (P ¼ 0.0129). In the multivariable model for progression-free survival, both posttransplant CR and PCLI remained significant (P ¼ 0.0018 and 0.0143, respectively).
Discussion
HDT and autologous stem cell transplantation remain the standard of care for patients with newly diagnosed multiple myeloma, especially younger individuals who are eligible for the procedure. Although it is doubtful that autologous stem cell transplantation results in a cure of this disease, it improves the response rates, relapse-free survival as well as overall survival. [7] [8] [9] The conventional approach to autologous transplantation in newly diagnosed myeloma has consisted of initial therapy aimed at tumor reduction, followed by stem cell harvest, conditioning therapy, and reinfusion of the stem cells. Studies demonstrating potential damage to stem cells with alkylating agents have resulted in these agents being removed from the initial therapy so as not to compromise stem cell collection.
12 Different combination regimens have been used for induction therapy in these patients, the most common one being the combination of vincristine, doxorubicin, and dexamethasone (VAD), which was initially introduced in the mid eighties. 17, 18 Given that dexamethasone is the most active component in the combination and based on reports of efficacy of dexamethasone used alone in myeloma, [19] [20] [21] as well as the known adverse effects with VAD, we treated a group of patients with single agent dexamethasone as induction therapy.
In this study, we have compared the results in this group of patients to a control group receiving VAD as initial therapy. The study group and the control group were very similar in terms of their baseline features at diagnosis, except for slightly higher proportion of patients with high b2M in the VAD group. The response to induction therapy was comparable between the two groups. The two groups also obtained similar responses to transplant without any significant differences in the transplant-related toxicity. The slower engraftment in the Dex group compared to the VAD group may be related to the differences in the stem cell mobilization practices that had been introduced over time and is not strictly comparable. The infused CD34 cell doses were comparable between the two groups. The overall and progression-free survival from transplant was comparable for the two groups at 1-year post transplant.
VAD was introduced as an effective combination therapy for use in alkylating agent-resistant myeloma and has since become one of the most commonly used regimens for myeloma therapy especially as initial therapy for patients going on to HDT. 13, 17, 18 Adverse events seen with VAD include myelosuppression, increased risk of deep vein thrombosis, neuropathy due to vincristine, sepsis and thrombotic phenomena from indwelling catheter, as well as potential cardiotoxicity due to doxorubicin. 17, 18, 22 In addition, it involves continuous infusion of adriamycin and vincristine over 4 days necessitating central venous access and possible hospitalization. The concept behind the VAD combination was the dose responsiveness of myeloma to dexamethasone as well as targeting of the slow cycling plasma cells with continuous infusion of doxorubicin and vincristine. 13 It is clear that dexamethasone is the most active agent within this combination and the contribution of vincristine and doxorubicin is open to debate. Use of Autologous transplantation in myeloma S Kumar et al vincristine, as a single agent has been associated with limited activity in patients with refractory myeloma in phase 2 trials. 23 Anthracyclines have activity in myeloma as a single agent. In the early studies it showed activity in patients resistant to melphalan and prednisone though responses were short lived. 24 Other anthracyclines like mitoxantrone, idarubicin, and epirubicin have also been studied in myeloma, alone or in combination with steroids and alkylating agents and have demonstrated varying degrees of activity. [25] [26] [27] [28] [29] Use of anthracyclines as a single agent has generally been associated with unsatisfactory response rates. In a study from the Nordic Myeloma study group, use of oral idarubicin in relapsed myeloma resulted in very few responses. 30 In another randomized trial evaluating melphalan prednisolone combination with and without doxorubicin, no advantage was found by adding doxorubicin. 31 The role of induction therapy in the long-term outcome of transplanted multiple myeloma is not clear. Its contribution to the outcome of transplant, both immediate and long term has not been studied systematically. Studies evaluating prognostic factors for HDT in myeloma suggest that the induction therapy has an important role to play. Studies have suggested that the disease status at the time of transplant has a prognostic value and those with relapsed disease have a shorter relapse-free survival. 32 Patients with active disease and those with disease not responsive to initial therapy have a higher tumor burden at the time of stem cell harvest. Hence, it is likely that reduction of tumor burden prior to stem cell harvest may have a positive effect on the post transplant outcome. From a practical standpoint, initial therapy to bring the disease under control would result in the improvement in performance status of many patients who present with advanced disease and allow them to proceed safely with transplant. In addition, improvement in serum creatinine in those presenting with renal insufficiency could potentially allow for HDT.
Observations, which would argue against the induction therapy being an important component, are the results of HDT in patients who have primary refractory disease. We as well as others have reported high response rates in these patients after HDT, comparable to those seen in patients with chemosensitive disease. 15, 33 Powles et al used high-dose melphalan (200 mg/m 2 ) with stem cell rescue as the initial therapy for newly diagnosed myeloma. Stem cells were collected from three patients at presentation after high-dose steroids and growth factors followed by high-dose melphalan. The patients were treated with C-VAMP following the HDT and a CR was achieved in all the patients. Long-term follow-up, however, is lacking.
Other investigators have reported on the efficacy of single agent dexamethasone for treatment of myeloma, especially for relapsed and/or refractory disease. Alexanian reported a 43% response rate (475% reduction in M protein) among 112 patients with newly diagnosed myeloma who were treated with intermittent courses of dexamethasone. 21 Although this was roughly 15% less than the response seen with VAD in a similar group of patients, serious complications were considerably less with the Dex alone (4 vs 27%). The estimated survival in these patients was comparable to that seen with VAD therapy. In another trial of dexamethasone used as a single agent in resistant myeloma, similar response rate to that with VAD was observed in primary-resistant patients. 19 However, VAD resulted in higher response rates in relapsed-resistant patients. In an ECOG pilot study of high-dose dexamethasone using a more dose-intensive strategy, Friedenberg et al observed a 40% response rate but also significant toxicity in previously heavily treated patients. 20 In a recent report from the MD Anderson Cancer Center, Anagnostopoulos et al 34 reported excellent results with single agent dexamethasone as induction therapy for newly diagnosed myeloma. They compared 47 patients receiving single agent dexamethasone with a historical control group of 97 patients who received VAD or an alkylating agent. The CR rate following transplant was 44% in this group of patients at 13 months follow-up. No difference was observed in terms of stem cells collected, tumor cell contamination of the graft, transplant-related toxicity, or engraftment kinetics between the two groups. It is not clear how the introduction of newer agents like thalidomide and other immunomodulatory drugs and the proteasome inhibitors would affect the choice of pre-transplant induction therapy. Particularly, the combination of thalidomide and dexamethasone has been studied and reported by us and the MD Anderson group. Response rates of 65-70% have been observed with this combination. 35, 36 The multicenter trial comparing Thalidomide plus dexamethasone vs dexamethasone alone has been completed and the results are awaited. Other trials are looking at combining newer agents like Revimid with dexamethasone.
Given this background, it is attractive to use an induction therapy that is easy to administer as well as to limit toxicity from therapy. Use of myelosuppressive therapy, in addition to the increased toxicity, may be associated with stem cell damage and may preclude a successful stem cell harvest. As demonstrated in this study, dexamethasone when used as a single agent has significant efficacy and can avoid the morbidity and risk associated with central venous access as well as the discomfort of continuous infusion and possible hospitalization. It also allows patients to proceed to transplantation without having received any pre-transplant cytotoxic therapy. The response rate to dexamethasone is comparable to that seen with the control population receiving VAD, which in turn appears to be similar to that reported with VAD in newly diagnosed myeloma. 17 Given these results, single agent dexamethasone appears to be an effective alternative to VAD as initial therapy for patients with newly diagnosed myeloma, proceeding to autologous stem cell transplantation. In fact, at our institution, newly diagnosed patients eligible for HDT are started on dexamethasone induction therapy if they are not participating in a clinical trial. Longterm follow-up of these patients will provide more valuable information. However, this study is limited by its retrospective nature and the small number of patients studied. These results need confirmation from randomized, prospective studies.
